ImmunityBio says bladder cancer therapy on track for filing, shares rise

Shares of drug developer ImmunityBio IBRX.O rise 2.11% to $8.24

Co says trial for its first-line non-muscle invasive bladder cancer treatment remains on track for final analysis and a supplemental U.S. marketing application in late 2026

Co says an independent monitoring committee found the late-stage trial had enough patients to test whether its cancer therapy, Anktiva, improves results when added to BCG, a standard bladder cancer treatment

Review was based on an interim look at 183 patients, or about half of those enrolled, who could be assessed for the main study goal - IBRX

IBRX shares were down over 22% in 2025